Jci_page_head_homepage_01 Jci_page_head_homepage_02
Zia A. Khan, Elisa Boscolo, Arnaud Picard, Sarah Psutka, Juan M. Melero-Martin, Tatianna C. Bartch, John B. Mulliken, Joyce Bischoff
Published in Volume 118, Issue 7
J Clin Invest. 2008; 118(7):2592–2599 doi:10.1172/JCI33493
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 1
HemSCs express VEGF-Rs and mesenchymal cell marker CD90.

(A) Flow cytometric analysis of HemSCs, BM-MSCs, NHDFs, and HDMECs. Each cell type was grown in the EBM-2/20% FBS and assayed at passage 6. Gray histograms show cells labeled with FITC- or PE-conjugated antibodies. Black lines show isotype-matched control FITC- or PE-conjugated antibodies. Incubation with anti-CD31 and anti–VEGF-R2 was carried out following saponin permeabilization of HemSCs, BM-MSCs, and NHDFs. (B) RT-PCR analysis of Oct-4 and AML1 in 2 different HemSCs, Hem 106 and 109, with BM-MSCs and NHDFs shown for comparison. Ribosomal S9 (rS9) served as a control.